Injectafer (ferric carboxymaltose) is an intravenous iron replacement medication prescribed to adult patients for the treatment of iron deficiency anemia. Research indicates that patients taking the iron replacement product are at high risk of developing hypophosphatemia (HPP), a condition that can be life-threatening. Injectafer lawsuits allege that consumers and the medical community were not adequately warned of Injectafer HPP risk and other adverse side effects.
